Unusual DNA binding modes for metal anticancer complexes [PDF]
, 2009 DNA is believed to be the primary target for many metal-based drugs. For example, platinum-based anticancer drugs can form specific lesions on DNA that induce apoptosis.
Pizarro, Ana M., Sadler, P. J.
core +1 more source
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability [PDF]
Cell Death & Disease, 2020 Abstract Resistance to chemotherapy remains the major cause of treatment failure in patients with colorectal cancer (CRC). Here, we identified TRIM25 as an epigenetic regulator of oxaliplatin (OXA) resistance in CRC. The level of TRIM25 in OXA-resistant patients who experienced recurrence during the follow-up period was significantly ...
Sha Zhou +9 more
openaire +5 more sources
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]
, 2007 We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross +2 more
core +1 more source
Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors [PDF]
, 2017 [Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy.
Ceresa, Cecilia +8 more
core +3 more sources
Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]
, 2015 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland +49 more
core +1 more source
Cell Death and Disease, 2022 Oxaliplatin resistance is a major challenge in the treatment of colorectal cancer (CRC). Many molecular targeted drugs for refractory CRC have been developed to solve CRC drug resistance, but their effectiveness and roles in the progression of CRC and ...
Xiaohui Shen +10 more
doaj +1 more source
Cells, 2022 Colorectal cancer is the second most common cancer in women, the third in men, and an important cause of cancer-related mortality. Recurrence and the development of chemotherapy resistance are major hindrances for patients’ treatment.
Vanessa Rodríguez-Fanjul +5 more
doaj +1 more source
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. [PDF]
, 2015 BackgroundDemethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.
Culotta, Kirk +15 more
core +2 more sources
LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5
Scientific Reports, 2022 A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated.
Chongsheng Xia +4 more
doaj +1 more source
Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]
, 2012 Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Allegra CJ +41 more
core +1 more source